Evidence map›Paper›PMID 39528477›Full record

ArticleNature communications2024

Crystallinity of covalent organic frameworks controls immune responses.

Arezoo Esrafili, Abhirami Thumsi, Madhan Mohan Chandra Sekhar Jaggarapu, Richard G Nile, Joshua Kupfer, Margaret Dugoni, Abhirami P Suresh, Taravat Khodaei, Huikang Qian, Anna Mathis and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Arezoo Esrafili *Chemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Abhirami Thumsi *Department of Pathology, School of Medicine, Case Western Reserve University, Ohio, OH, USA.
Madhan Mohan Chandra Sekhar JaggarapuDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Richard G NileChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Joshua KupferChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.ORCID 0009-0006-9306-3642
Margaret DugoniBiomedical Engineering, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA.
Abhirami P SureshDepartment of Pathology, School of Medicine, Case Western Reserve University, Ohio, OH, USA.
Taravat KhodaeiDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Huikang QianDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Anna MathisDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Brandon KimDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.ORCID 0009-0006-7484-9340
Srivatsan J SwaminathanSchool of Life Sciences, Arizona State University, Tempe, AZ, USA.
Wei SunDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.ORCID 0000-0003-3152-0124
Yeo Weon SeoDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Kelly LintecumBiomedical Engineering, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA.ORCID 0000-0002-4968-2781
Sanmoy PathakDepartment of Biomedical Engineering, Case Western Reserve University, Ohio, OH, USA.
Xinbo TongChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Julianne L HollowayChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Kailong JinChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Abhinav P AcharyaDepartment of Pathology, School of Medicine, Case Western Reserve University, Ohio, OH, USA. axa1826@case.edu.ORCID 0000-0002-9361-2764

Funding

Biomaterials-based metabolic rescue of dendritic cells for vaccine designR01AI155907 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ACHARYA, ABHINAV · 2021 to 2025
$1.7M
Local immunometabolism modulating biomaterials for immunosuppressive applicationsR01AR078343 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI ACHARYA, ABHINAV · 2021 to 2025
$1.6M
ACS | American Chemical Society Petroleum Research Fund (ACS Petroleum Research Fund) FP00030762NIAID NIH HHS R01 AI155907NIAMS NIH HHS R01 AR078343U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01 AI155907-01
6 · The paper itself

Abstract

Biomaterials can act as pro- or anti-inflammatory agents. However, effects of biomaterials crystallinity on immune responses are poorly understood. We demonstrate that the adjuvant-like behaviour of covalent organic framework (COF) biomaterial is dependent on its crystallinity. COF crystallinity is inversely correlated with the activation of mouse and human dendritic cells (DC), but with antigen presentation by mouse DCs only. Amorphous COFs upregulates NFkB, TNF, and RIG-I signalling pathways, as well as the chemotaxis-associated gene Unc5c, when compared to crystalline COFs. Meanwhile, Unc5c inhibition disrupts the correlation between crystallinity and DC activation. Furthermore, COFs with the lowest crystallinity admixed with chicken ovalbumin (OVA) antigen prevent OVA-expressing B16F10 tumour growth in 60% of mice, with this protection associated with the induction of antigen-specific, pro-inflammatory T cell. The lowest crystalline COFs admixed with TRP2 antigen can also prevent non-immunogenic YUMM1.1 tumour growth in 50% of mice. These findings demonstrate that the crystallinity of biomaterials is an important aspect to consider when designing immunotherapy for pro- or anti-inflammatory applications.

Indexed as

Dendritic CellsMice, Inbred C57BLOvalbuminAnimalsAntigen PresentationBiocompatible MaterialsCrystallizationFemaleHumansMelanoma, ExperimentalMetal-Organic FrameworksMiceNF-kappa BSignal TransductionTumor Necrosis Factor-alphaBiocompatible MaterialsMetal-Organic FrameworksNF-kappa BOvalbuminTumor Necrosis Factor-alpha

Identifiers

PMID39528477
PMCPMC11555212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.